Academic Jobs Logo

Rate My Professor David Lewis

CRUK Scotland Institute

Manage Profile
5.00/5 · 1 review
5 Star1
4 Star0
3 Star0
2 Star0
1 Star0
5.05/4/2026

Creates a collaborative learning environment.

About David

Professor David Lewis is Professor of Molecular Imaging at the CRUK Scotland Institute and the University of Glasgow School of Cancer Sciences. Since 2017, he has served as Group Leader at the CRUK Scotland Institute, where he founded and leads the Molecular Imaging research group. He also heads the Translational Molecular Imaging centre, a shared resource advancing novel imaging technologies including PET/MRI, clinical PET/CT scanners, cyclotron, and radiosynthesizers for cancer research across Glasgow sites. His research employs state-of-the-art PET/MRI imaging, metabolomics, and genomics to investigate the spatial and temporal dynamics of metabolic heterogeneity in living tumours driven by genetic mutations and microenvironmental factors. This work aims to develop non-invasive imaging methods to classify tumours, assess treatment response, and enable precision medicine in cancers such as lung, colorectal, liver, and others.

Lewis is Imaging Lead for the CRUK RadNet Centre of Excellence in Glasgow, a CRUK RadNet Steering Board member, and founder and chair of the National CRUK RadNet Molecular Imaging and Radiotherapy Working Group. He is a co-investigator on the CANCAN Cancer Grand Challenges team, utilizing total-body PET to study metabolic rewiring in cancer cachexia. Key publications include 'Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging' (Clinical Cancer Research, 2024), 'Human-correlated genetic models identify precision therapy for liver cancer' (Nature, 2025), 'A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma' (Disease Models & Mechanisms, 2025), 'Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo' (Cancer & Metabolism, 2023), and 'Spatial molecular plasticity underpins lethal morphologies in lung adenocarcinoma' (Modern Pathology, 2026). His contributions enhance molecular phenotyping, biomarker development, and translation to clinical diagnostics.